Danske Bank A S Has $159,000 Position in Henry Schein, Inc. $HSIC

Danske Bank A S cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 88.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,100 shares of the company’s stock after selling 15,485 shares during the quarter. Danske Bank A S’s holdings in Henry Schein were worth $159,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. CYBER HORNET ETFs LLC acquired a new position in Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein in the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein in the fourth quarter worth $30,000. Steph & Co. bought a new position in shares of Henry Schein during the fourth quarter worth $52,000. Finally, Tema Etfs LLC bought a new position in shares of Henry Schein during the fourth quarter worth $56,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Henry Schein

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total transaction of $478,740.00. Following the sale, the executive vice president directly owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Stanley M. Bergman sold 43,812 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the sale, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This represents a 10.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 105,911 shares of company stock worth $8,574,982. Insiders own 0.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on HSIC shares. Citigroup began coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective for the company. Morgan Stanley reissued an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Barrington Research set a $97.00 price target on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Wall Street Zen lowered Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Finally, UBS Group reiterated a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a report on Wednesday. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $86.83.

Key Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q1 results beat expectations: HSIC reported $1.32 EPS on $3.37B revenue, topping consensus and showing 6.3% revenue growth and margin improvement — a core reason investors bought the stock after the print. Henry Schein Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dental strength and margin expansion were highlighted by management and reporters, supporting the beat and the company’s message of market‑share gains. Reuters: Henry Schein reaffirms annual profit forecast, beats Q1 estimates
• Positive Sentiment: Analyst commentary and screens emphasize HSIC’s value characteristics (attractive P/E, stable cash flows), with Zacks flagging the stock as a strong value pick for some investors. Here’s Why Henry Schein (HSIC) is a Strong Value Stock
• Neutral Sentiment: Company reaffirmed FY‑2026 EPS guidance (5.230–5.370) and revenue range roughly in line with consensus — guidance was maintained, not raised, so this is reassuring but not a catalyst. Press release / guidance
• Neutral Sentiment: Earnings call transcript and slide deck are available for deeper detail on segment trends and margin drivers — useful for investors doing diligence. Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Several roundup pieces note mixed analyst views on HSIC — debate centers on execution of margin improvement and growth sustainability rather than any single, clear directional factor. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: At least one shop cut its price target (Mizuho lowered PT from $88 to $82 and set a neutral rating), which can pressure the stock via reduced analyst upside and sentiment. Tickerreport: Mizuho price target cut
• Negative Sentiment: Despite the beat, the stock is trading lower with above‑average volume (investors appear to be selling into the print, possibly locking in gains or reacting to the mixed analyst tone). MarketWatch: stock underperforms peers

Henry Schein Trading Down 2.6%

Shares of NASDAQ:HSIC opened at $72.44 on Thursday. The company’s 50-day moving average price is $76.32 and its two-hundred day moving average price is $75.00. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.29. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.76. The stock has a market capitalization of $8.31 billion, a PE ratio of 21.89, a price-to-earnings-growth ratio of 2.20 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the previous year, the business earned $1.15 earnings per share. Henry Schein’s quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities analysts forecast that Henry Schein, Inc. will post 5.3 EPS for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.